Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma:a single-center experience
- Author:
Gaurav PRAKASH
1
;
Arihant JAIN
;
Kamalkant SAHU
;
Amanjit BAL
;
Charanpreet SINGH
;
Rajender BASHER
;
Harmandeep SINGH
;
Kundan MISHRA
;
Aditya JANDIAL
;
Deepesh LAD
;
Alka KHADWAL
;
Radhika SRINIVASAN
;
Ashim DAS
;
Neelam VARMA
;
Subhash VARMA
;
Pankaj MALHOTRA
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Blood Research 2021;56(3):134-140
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:This study evaluated the outcomes of patients with refractory/relapsed Hodgkin lymphoma (RRHL) treated with a bendamustine-based regimen in combination with ifosfamide, etoposide, and vinorelbine (VIBE).
Methods:Consecutive RRHL patients who were treated with the VIBE regimen were identified and studied for clinicopathologic characteristics, response to VIBE regimen, event-free survival (EFS), and feasibility of an autologous stem-cell transplant (autoSCT).
Results:In total, 24 patients received the VIBE regimen, and a median of 3 cycles were administered. In this cohort, 80% of the patients had received ≥2 prior lines of therapy. The overall and complete response rates with VIBE were 79% and 42%, respectively. After a median follow-up (following VIBE regimen) of 14 months (range, 3‒76), the 3-year EFS and OS were 46% and 74%, respectively. Of the eligible patients, 92% underwent successful AutoSCT. The mean CD34+ cell count in the autograft was 5.5×106/kg (SD 2.07). Neutropenia was the commonest hematologic toxicity and it was observed in 42% of the patients. However, only 9% of the patients developed grade III/IV febrile neutropenia. Chemotherapy-induced nausea and vomiting were the second most common grade III/IV toxicities in our cohort of patients.
Conclusion:In this retrospective analysis, the combination regimen, VIBE, has shown good efficacy in heavily pre-treated patients with RRHL without compromising stem cell collection. These encouraging results provide a rationale for further development of this regimen.
